Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced today it has promoted Lode Debrabandere, Ph.D. to the role of Chief Operating Officer (COO) reporting directly to Chief Executive Officer, C. Randal Mills, Ph.D. Dr. Debrabandere has been with Osiris since 2006 in various leadership positions, most recently serving as Senior Vice President for Therapeutics. During his time at Osiris, Dr. Debrabandere has played a key role in the development and approval of Osiris’ products including Prochymal® ( remestemcel-L), which earlier this year became the world’s first stem cell drug to be granted marketing approval by an internationally recognized regulatory authority.
"This is an exciting time at Osiris as we move rapidly into the commercialization of stem cell medicine," said C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris. "Over the past six years, Lode has proven to be an effective leader and his unique skill set will become increasingly more important at Osiris as we move forward."
Prior to joining Osiris, Dr. Debrabandere served as Vice President of Global Marketing with Bristol-Myers Squibb where he was the Global Brand Leader for Abilify®. Previously, Dr. Debrabandere led the Marketing department of UCB Pharma, Inc., focusing in the areas of allergy (Zyrtec™) and neurology (Keppra™). Prior to that, he was the Head of worldwide clinical operations at UCB Pharma, Inc. Dr. Debrabandere earned an M.B.A., a Ph.D. in toxicology and a Pharm. D. degree, all from the University of Leuven, Belgium.
About Osiris TherapeuticsOsiris Therapeutics, Inc., having developed the world’s first approved stem cell drug, Prochymal, is the leading stem cell company. The company is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets. In Biosurgery, Osiris currently markets Grafix® for burns and chronic wounds, and Ovation® for orthopedic applications. Osiris is a fully integrated company with capabilities in research, development, manufacturing and distribution of stem cell products. Osiris has developed an extensive intellectual property portfolio to protect the company's technology, including 48 U.S. and 144 foreign patents.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV